medigraphic.com
SPANISH

Revista Médica MD

  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2019, Number 3

<< Back Next >>

Rev Med MD 2019; 10.11 (3)

Myelod Sarcoma: an uncommon entity

Rodríguez-Bautista E, Méndez-González A, Martínez-Coronel J
Full text How to cite this article

Language: Spanish
References: 10
Page: 245-249
PDF size: 603.04 Kb.


Key words:

Acute myeloid leukemia, diagnosis, Granulocytic sarcoma, Myeloid sarcoma, treatment.

ABSTRACT

Myeloid Sarcoma (MS), also called Acute Extramedullary Myeloid Leukemia, Extramedullary Myeloid Tumor or Granulocytic Sarcoma, is a rare neoplastic condition characterized by the appearance of one or more tumor masses, consisting of immature myeloid cells in an extramedullary site, commonly arising in the skin, bone or lymph nodes, although it can appear anywhere in the body.
We present the case of a 39-year-old male patient with cutaneous clinical manifestation, nocturnal diaphoresis and intermittent fever.
MS occurs more frequently in association with Acute Myeloid Leukemia (AML), affecting 2.5 to 9.1% of these patients; When it is detected before the clinical signs of leukemia and in association with a normal bone marrow biopsy is described as primary or isolated MS, this rare pathology has an incidence of 2/1 000 000 in the adult population, thus, the clinical and pathological diagnosis can be a challenge.


REFERENCES

  1. Cristina Campidelli, Claudio Agostinelli, Richard Stitson and Stefano A. Pileri. Myeloid Sarcoma: Extramedullar y Manifestation of Myeloid Disorders. Am J Clin Pathol. 2009;132(3):426-437

  2. Stefanidakis M, Karjalainen K, et al. Role of leukemia cell invadosome in extramedullary infiltration. Blood. 2009; 114:3008-3017

  3. Avni B, Koren-Michowitz M. Myeloid sarcoma: cur rent approach and therapeutic options. Therapeutic Advances in Hematology. 2001 Oct; 2(5)

  4. Almond LM, Charalampakis M, Ford SJ, Gourevich D, Desai A. Myeloid Sarcoma: Presentation, Diagnosis and Treatment. Clin Lymphoma Myeloma Leuk. 2017;17(5):263-267

  5. Pileri SA, Ascani S, et al. Myeloid sarcoma: clinicopathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia. 2007;21(2):340–350

  6. Batia Avni and Maya Koren-Michowitz. Myeloid sarcoma: current approach and therapeutic options. Ther Adv Hematol. 2011; 2(5):309 316.

  7. Yossi S., de Talhouet S., et al. Radiotherapy of chloroma or granulocytic sarcoma: A literature review. Cancer Radiother. 2016; 21(1):60-5

  8. Bakst RL, Tallman MS, Douer D, Yahalom J. How I treat extramedullary acute myeloid leukemia. Blood. 2011; 118:3785-3793.

  9. Lan T.Y., Lin D.T., Tien H.F., Yang R.S., Chen C.Y., Wu K. Prognostic Factors of Treatment Outcomes in Patients with Granulocytic Sarcoma. Acta Hematol. 2009; 122:238-46

  10. Yamauchi K. YM. Comparison in Treatments of Nonleukemic Granulocytic Sarcoma. Report of Two Cases and a Review of 72 Cases in the Literature. Cancer. 2002;94(6):1739-46




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Rev Med MD. 2019;10.11